TFF Pharmaceuticals to Present at the BIO CEO & Investor Digital Conference
February 12 2021 - 8:30AM
Business Wire
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative drug products based on its patented Thin Film Freezing
(TFF) technology platform, will participate in the 2021 BIO CEO
& Investor Digital Conference, being held virtually on February
16-18, 2021.
Glenn Mattes, President & CEO of TFF Pharmaceuticals, is
scheduled to give a pre-recorded company presentation at the
conference. The recording will be available on-demand to registered
conference attendees via the BIO conference portal for 30 days and
can be accessed in the Investor Relations section of the TFF
Pharmaceuticals website.
The Company will also participate in investor and partnering
meetings with conference attendees during the event.
About TFF Pharmaceuticals’ Thin Film Freezing technology
platform TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform
was designed to improve the solubility and absorption of poorly
water-soluble drugs and is particularly suited to generate dry
powder particles with properties targeted for inhalation delivery,
especially to the deep lung, an area of extreme interest in
respiratory medicine. The TFF process results in a “Brittle Matrix
Particle,” which possesses low bulk density, high surface area, and
typically an amorphous morphology, allowing the particles to
supersaturate when contacting the target site, such as lung tissue.
Based upon laboratory experiments the aerodynamic properties of the
particles are such that the portion of a drug deposited to the deep
lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals TFF Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative drug products based on its patented Thin
Film Freezing, or TFF, technology platform. Early testing confirms
that the TFF platform can significantly improve the solubility and
absorption of poorly water-soluble drugs, a class of drugs that
comprises approximately one-third of the major pharmaceuticals
worldwide, thereby improving their pharmacokinetics. TFF
Pharmaceuticals has two lead drug candidates: Voriconazole
Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans
to add to this pipeline by collaborating with large pharmaceutical
partners. The TFF Platform is protected by 42 patents issued or
pending in the US and internationally. To learn more about TFF
Pharmaceuticals and its product candidates, visit the Company’s
website at https://tffpharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210212005267/en/
Company Contacts: Glenn Mattes President and CEO TFF
Pharmaceuticals, Inc. gmattes@tffpharma.com 737-802-1973 Kirk
Coleman Chief Financial Officer TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com 817-989-6358 Investor Relations and Media
Contact: Paul Sagan LaVoieHealthScience
psagan@lavoiehealthscience.com 617-953-4779
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Mar 2024 to Apr 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Apr 2023 to Apr 2024